Revolutionary Blood Test Detects Seven Times More Cancers Than Standard Screening

Breakthrough Results Transform Cancer Detection

A groundbreaking blood test called Galleri has shown remarkable success in detecting cancer years before symptoms appear, potentially revolutionizing how doctors screen for the disease. In the largest U.S. study of its kind, adding Galleri to recommended screenings for breast, cervical, colorectal, and lung cancers led to a more than seven-fold increase in the number of cancers found within a year. The test works by analyzing fragments of DNA circulating in the bloodstream, identifying over 50 different cancer types through a simple blood draw.

There are more than 200 types of cancer, 70% of which have no screening test. This gap represents a critical vulnerability in current healthcare, as "approximately 70% of cancer deaths come from cancers that do not have standard-of-care screening and are typically caught too late," according to researchers at Oregon Health & Science University.

More than half (53.5%) of the new cancers detected by Galleri were stage I or II and more than two-thirds (69.3%) were detected at stages I-III. This early detection capability represents a fundamental shift from current screening methods, which typically focus on just four or five cancer types.

How the Technology Works

Galleri employs a blood draw to detect circulating tumor DNA, identifying multiple cancer types before symptoms arise. The test achieved impressive accuracy metrics in recent trials. The test was able to detect a cancer signal in 216 participants, and of these participants, 133 were diagnosed with cancer. The positive predictive value, or the likelihood of receiving a cancer diagnosis following a positive test result, was 61.6% — much higher than what was found in previous trials (43% to 50%).

Researchers at Johns Hopkins found that fragments of tumor DNA can appear in the bloodstream up to three years before a cancer diagnosis, offering a potentially revolutionary window for early detection and treatment. Other research teams have developed complementary approaches, including HPV-DeepSeek, a blood test that can detect HPV-linked head and neck cancers nearly a decade before diagnosis. By finding viral DNA in the bloodstream, the test achieved 99% sensitivity and specificity.

Real-World Impact and Clinical Trials

The PATHFINDER 2 study, involving nearly 36,000 participants across the United States and Canada, represents the largest interventional study of multi-cancer early detection technology to date. Approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. This finding underscores the test's potential to fill critical gaps in current cancer screening protocols.

The clinical performance of Galleri has been rigorously established in several studies, and the NHS-Galleri trial was designed to demonstrate population-level impact through the reduction of late stage cancer diagnoses and increased cancer detection rate within the NHS to inform a decision about a national screening program in England. The parallel UK study, involving 142,000 participants, showed "the substantial reduction in Stage IV cancer diagnoses, as well as the continued strong Galleri test performance metrics."

Path to Widespread Adoption

Data from PATHFINDER 2 will be submitted to the Food and Drug Administration as part of the Galleri premarket approval application in the first quarter of 2026, with a potential decision expected in 2027. The test already operates under FDA Breakthrough Device Designation, which expedites the review process for technologies addressing unmet medical needs.

While the technology shows tremendous promise, challenges remain. Ruth Etzioni, a biostatistician who studies cancer screening, said it was unclear whether the cancer cases Galleri detected were actually caught earlier than they would have been otherwise with more traditional screening methods. "It's very difficult to judge the clinical importance of these results," Etzioni said. "The extent to which the fate of these cancers is being changed by being diagnosed by the test is unclear."

Despite these questions, researchers envision a future where multi-cancer blood tests become routine healthcare. Researchers said they envision a future where MCED blood tests are approved by the FDA and commonplace — part of routine health care given alongside standard cancer screenings like colonoscopies and mammograms. "We have all of these cancers that are causing cancer-related mortality every single year, but we don't know about them until it's often too late," researchers noted. "This test gives us a way to potentially screen for those cancers, find it early and give our patients a much greater chance of being cured." The convergence of multiple successful trials suggests that blood-based cancer detection may soon transform from experimental technology into standard medical practice.